Edition:
United Kingdom

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

39.50USD
20 Apr 2018
Change (% chg)

$0.10 (+0.25%)
Prev Close
$39.40
Open
$39.10
Day's High
$40.05
Day's Low
$38.95
Volume
94,980
Avg. Vol
262,320
52-wk High
$49.90
52-wk Low
$11.80

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: --
Market Cap(Mil.): $495.06
Shares Outstanding(Mil.): 30.56
Dividend: --
Yield (%): --

Financials

  ATRA.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -3.33 -- --
ROI: -36.94 1.58 14.38
ROE: -37.81 2.41 16.07

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

01 Mar 2018

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING ‍​ Source text (http://bit.ly/2CKPbcB) Further company coverage:

27 Feb 2018

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

27 Feb 2018

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

27 Feb 2018

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

21 Feb 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

10 Jan 2018

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

05 Jan 2018

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

02 Jan 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

29 Dec 2017

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

07 Dec 2017

Competitors

  Price Chg
Biogen Inc (BIIB.OQ) $263.02 --
Bayer AG (BAYGn.DE) €98.33 -0.67
Bayer AG (BAYE.F) -- --
Teva Pharmaceutical Industries Limited (TEVA.TA) 6,307.00 -54.00
Merck KGaA (MRCG.DE) €82.00 -0.02
Sanofi SA (SASY.PA) €65.72 +0.44
Novartis AG (NOVN.S) CHF75.84 -0.24
Roche Holding Ltd. (ROG.S) CHF216.40 +0.75
Roche Holding Ltd. (RO.S) CHF220.60 +0.60

Earnings vs. Estimates